SlideShare una empresa de Scribd logo
Institute of Health Science
Department of Nursing
Postgraduate Program of Adult Health Nursing
Chronic Glomerulonephritis Seminar Presentation
Set By: Rebira Workineh (AHN Student)
Rebira W. (AHN student)
2/13/2024
1
Objectives
Rebira W. (AHN student)
At the end of this session, the participants will be able to:
 Define chronic glomerulonephritis
 Identify the development of chronic glomerulonephritis
 Explain etiologies of chronic glomerulonephritis
 Understand how to diagnose chronic glomerulonephritis
 Describe the differential diagnosis of chronic glomerulonephritis
 Identify possible management for patients with chronic glomerulonephritis
2/13/2024
2
Outlines
2/13/2024
Rebira W. (AHN student)
3
 Introduction to CGN
 Epidemiology
 Pathophysiology
 Etiology
 Clinical manifestations
 Investigations
 Differential diagnosis
 Medical mgt.
 Nursing mgt.
 Prevention
 Complications
 References
Introduction to CGN
2/13/2024
Rebira W. (AHN student)
4
 Nearly all forms of AGN have a tendency to progress to chronic glomerulonephritis.
 CGN is characterized by irreversible & progressive glomerular & tubulointerstitial
fibrosis, leading to a reduction in the GFR & retention of uremic toxins.
 If disease progression is not halted with therapy, it results in CKD, ESRD, & CVD.
 CGN is the 3rd leading cause of CKD, & accounts for about 10% of all patients on
dialysis.
(Kawasaki Y et al, 2011)
Introduction to CGN Cont’d…
2/13/2024
Rebira W. (AHN student)
5
Definition
 CGN is a kidney disorder caused by slow, cumulative damage and scarring, usually
by inflammation, of the tiny blood filters in the kidneys.
 These filters, known as glomeruli, remove waste products from the blood.
 Inflammation typically results in one or both of the nephrotic or nephritic
syndromes.
The National Kidney Foundation
2/13/2024
Rebira W. (AHN student)
6
 NKF defines CKD on the basis of either of the following criteria
o Evidence of kidney damage based on abnormal urinalysis results or
structural abnormalities observed on ultrasound images
o A GFR of < 60 mL/min for 3 months or longer
According to this criteria, the NKF developed guidelines that classify the progression
of renal disease into five stages
 This classification includes treatment strategies for each progressive level as follow
The NKF Cont’d…
2/13/2024
Rebira W. (AHN student)
7
Stage 1
 This stage is characterized by kidney damage with a normal GFR - ≥ 90 mL/min
 The action plan consists of diagnosis and treatment, treatment of comorbid conditions, slowing of the
progressing of kidney disease, and reduction of CVD risks
Stage 2
 This stage is characterized by kidney damage with a mild decrease in the GFR- 60-90 mL/min
 The action plan is estimation of the progression of kidney disease
The NKF Cont’d…
2/13/2024
Rebira W. (AHN student)
8
Stage 3
 This stage is characterized by a moderately decreased GFR- 30-59 mL/min
 The action plan consists of evaluation and treatment of complications
Stage 4
 This stage is characterized by a severe decrease in the GFR - 15-29 mL/min
 The action plan is preparation for renal replacement therapy
Stage 5
 This stage is characterized by kidney failure
 The action plan is kidney replacement if the patient is uremic
Epidemiology
2/13/2024
Rebira W. (AHN
student)
9
 In the United States, CGN is the 3rd leading cause of ESRD
 It accounts for 10% of patients on dialysis
 In Japan and some Asian countries, CGN has accounted for as many as 40% of
patients on dialysis
 However, subsequent data suggest that in Japan, the rate of CGN in patients on
dialysis is 28%.
 The cause of this decline rate is not known
(Nakai S et al, 2004)
2/13/2024
Rebira W. (AHN student)
10
Etiology
2/13/2024
Rebira W. (AHN student)
11
 The progression from AGN to CGN is variable, based on the cause of the condition
 Complete recovery of renal function occurs in patients with poststreptococcal
glomerulonephritis
 Other glomerulonephritis, such as IgA nephropathy, often has a relatively benign
course
 Many do not progress to ESRD
 Progression patterns may be summarized as follows
Etiology Cont’d…
2/13/2024
Rebira W. (AHN student)
12
Rapidly progressive glomerulonephritis or crescentic glomerulonephritis
 About 90% of patients progress to ESRD within weeks or months
Focal segmental glomerulosclerosis
 About 80% of patients progress to ESRD in 10 years
 This form may be related to HIV infection
Membranous nephropathy
 About 20-30% of patients with membranous nephropathy progress to CRF &
ESRD in 10 years
Etiology Cont’d…
2/13/2024
Rebira W. (AHN student)
13
Membranoproliferative glomerulonephritis
 About 40% of patients with membranoproliferative glomerulonephritis progress to
CRF & ESRD in 10 years
IgA nephropathy
 About 10% of patients with IgA nephropathy progress to CRF & ESRD in 10
years
Poststreptococcal glomerulonephritis
 About 1-2% of patients with poststreptococcal glomerulonephritis progress to CKD
& ESRD
Etiology Cont’d…
2/13/2024
Rebira W. (AHN student)
14
Lupus nephritis
 About 20% of patients with lupus nephritis progress to CRF& ESRD in 10 years
 The presence of antineutrophil cytoplasmic antibody is also an independent risk
factor for poor renal outcome.
(Wang Y et al, 2016)
Pathophysiology
2/13/2024
Rebira W. (AHN student)
Reduction in nephron mass from the initial injury reduces the GFR
This reduction leads to hypertrophy and hyperfiltration of the remaining nephrons
and to the initiation of intraglomerular hypertension
These changes occur in order to increase the GFR of the remaining nephrons, thus
minimizing the functional consequences of nephron loss
15
The changes, however, are ultimately detrimental because they lead to
glomerulosclerosis & further nephron loss
Pathophysiology Cont’d…
2/13/2024
Rebira W. (AHN student)
16
 In early renal disease, decline in the GFR leads to slight increases in serum
creatinine levels
 Azotemia (i.e., a rise in blood urea nitrogen & serum creatinine levels) is
apparent when the GFR decreases to < 60-70 mL/min
 Reduction in the GFR also results in the following
Pathophysiology Cont’d…
2/13/2024
Rebira W. (AHN student)
17
 Decreased production of erythropoietin, thus resulting in anemia
 Decreased production of vitamin D, resulting in hypocalcemia, secondary
hyperparathyroidism, hyperphosphatemia, & renal osteodystrophy
 Reduction in acid, potassium, salt, and water excretion, resulting in acidosis,
hyperkalemia, hypertension, & edema
 Platelet dysfunction, leading to increased bleeding tendencies
Clinical Manifestations
2/13/2024
Rebira W. (AHN student)
18
Symptoms
 Weakness and fatigue
 Loss of energy, appetite, and weight
 Pruritus
 Early morning nausea and vomiting
 Change in taste sensation
 Reversal in sleep pattern
 Peripheral neuropathy
 Seizures
 Tremors
Clinical Cont’d…
2/13/2024
Rebira W. (AHN student)
19
Signs
 Hypertension
 Jugular venous distention
 Pulmonary rales
 Pericardial friction rubs in pericarditis
 Tenderness in the epigastric region or blood in the stool
 Decreased sensation and asterixis
Investigations
2/13/2024
Rebira W. (AHN student)
20
Clinical findings
 History collection
 Physical examination
Urinalysis
 The presence of dysmorphic RBCs, albumin, or RBC casts suggest
glomerulonephritis as the cause of kidney failure
(Edgar V Lerma et al, 2022)
Investigations Cont’d…
2/13/2024
Rebira W. (AHN student)
21
Urinary protein excretion
 Estimated by calculating the protein to creatinine ratio on spot morning urine
sample
Complete blood count
 Anemia is a significant finding in patients with some decline in the GFR
 Is the result of marked impairment of erythropoietin production & alterations
in iron absorption that accompany CKD from ferroprotein and FGF23
Investigations Cont’d…
2/13/2024
Rebira W. (AHN student)
22
Serum chemistry
 Serum creatinine & BUN levels are elevated
 Impaired excretion of potassium, free water, & acid results in hyperkalemia,
hyponatremia, and low serum bicarbonate levels, respectively
 Impaired vitamin D-3 production results in hypocalcemia, hyperphosphatemia, and
high levels of parathyroid hormone
 Low serum albumin levels may be present if uremia interferes with nutrition or if
the patient is nephrotic
Investigations Cont’d…
2/13/2024
Rebira W. (AHN student)
23
Renal biopsy
 Kidney biopsy is usually unnecessary
Imaging Studies
 Ultrasound: Presence of both kidneys, size & exclude structural lesions that
may be responsible for azotemia
Differential Diagnosis
2/13/2024
Rebira W. (AHN
student)
24
 Azotemia, uremia, chronic kidney disease
 Crescentic glomerulonephritis
 Diffuse proliferative glomerulonephritis
 Glomerulonephritis associated with non-streptococcal infection
 Membranoproliferative glomerulonephritis
 Membranous glomerulonephritis
 Poststreptococcal glomerulonephritis
 Rapidly progressive glomerulonephritis
Management- Diet & Activity
2/13/2024
Rebira W. (AHN
student)
25
Diet
 Protein restriction (0.4 to 0.6 mg/kg/day)
 Slow the decline in GFR and reduce hyperphosphatemia (serum phosphate > 5.5
mg/dl) in patient with serum creatinine levels > 4 mg/dl
 Should follow low potassium diets (2000-3000 mg/dl)
Activity
 Patient should increase their activity level as tolerated
 This may aid in blood pressure control
Pharmacologic Therapy
2/13/2024
Rebira W. (AHN student)
26
BP Management
 Angiotensin converting enzyme inhibitors are the first treatment of choice
 Angiotensin II receptor blockers are used to retard the progression of CKD in
patient with diabetic and nondiabetic nephropathy
 Combination of ACEIs and ARBs- to achieve better pressure control & preservation
of kidney function
Pharmacologic…
2/13/2024
Rebira W. (AHN student)
27
Diuretics
 Are used to treat edema & hypertension
 Increase urine excretion by inhibiting sodium and chloride transporters
 Loop and thiazide are among classes of diuretics
 Examples: Furosemide (Lasix), bumetanide, torsemide, ethacrynic acid &
hydrochlorothiazide, metolazone
 Others: Beta blockers, calcium channel blockers, alpha1 antagonists, direct
vasodilators, etc.
Pharmacologic…
2/13/2024
Rebira W. (AHN student)
28
Fibrosis inhibition
 Progressive fibrosis is the hallmark of chronic glomerulonephritis
 Inhibitors of fibrosis is intended to slow the progression
 Pirfenidone is the best candidate, inhibits transforming growth factor & collagen
synthesis
 Others: Mineralocorticoid antagonists, nonsteroidal mineralocorticoid antagonists
(better, b/c the former induce hyperkalemia)
(DeFronzo RA et al ,2022)
Pharmacologic…
2/13/2024
Rebira W. (AHN student)
29
Sodium bicarbonate
 Reduce tubulointerstitial injury & endothelin production
 Slow progressive kidney damage
 In one study on patients with advanced kidney failure, the administration of sodium
bicarbonate preserved GFR decline
 Even in patients with relatively preserved GFR in stage 2 CKD, the administration of
sodium bicarbonate was shown to preserve kidney function over 5 years
(I de Brito-Ashurst et al, 2009 & Mahajan A et al, 2010)
Renal Replacement Therapy
2/13/2024
Rebira W. (AHN student)
30
 These options of renal replacement therapy are used when GFR falls below 20-25
ml/min
 Renal transplantation must explored when GFR falls below 20 ml/min
 Hemodialysis
 Peritoneal dialysis
 Renal transplantation
Nursing Management
2/13/2024
Rebira W. (AHN student)
31
Nursing diagnosis
Acute pain R/T inflammation of renal cortex AEB facial expressions & verbalization of patient
Goals
To reduce pain
Intervention
Assess pain characteristics
Provide comfort devices, quite environment and calm activities
Administer the analgesic according to physician order
Nursing Management Cont’d…
2/13/2024
Rebira W. (AHN student)
32
Nursing diagnosis
 Excess fluid volume R/T accumulation of fluid in the body AEB edema & weight gain.
Goal
 To maintain the fluid volume
Intervention
 To change the position frequently
 To elevate the edematous extremities
 To administer the diuretics to promote the diuresis
 To administer the albumin helps in shifting the fluid from the ISC to IVC
Nursing Management Cont’d…
2/13/2024
Rebira W. (AHN student)
33
Nursing diagnosis
 Ineffective breathing pattern R/T accumulation of fluid in the peritoneal cavity AEB
respiration rate, dyspnea.
Goal
 To improve the breathing pattern
Intervention
 Instruct the patient to perform the deep breathing exercise
 To provide the semi-fowler position
 Encourage the rest between the activities to avoid the overexertion
Prevention
2/13/2024
Rebira W. (AHN student)
34
 One should seek medical assistance as soon as possible if they have impetigo or a
sore throat due to a strep infection.
 Follow safe-sex guidelines and abstain from intravenous drug use to prevent
infections like HIV & hepatitis, which can cause some types of glomerulonephritis.
 Control high blood pressure to reduce the risk of kidney damage from
hypertension.
 In order to help avoid diabetic nephropathy, control blood sugar.
Complication
 Metabolic acidosis
 Pericarditis, pulmonary edema
 Uremic encephalopathy
 Uremic gastrointestinal bleeding
 Uremic neuropathy
 Severe anemia & hypocalcaemia
 Hyperkalemia
2/13/2024
Rebira W. (AHN student)
35
References
2/13/2024
Rebira W. (AHN student)
36
 Kawasaki Y, (2011). Mechanism of onset and exacerbation of chronic
glomerulonephritis and its treatment.
 Nakai S, et al, (2006). An overview of regular dialysis treatment in Japan (as of 31
December 2004).
 de Brito-Ashurst I, et al, (2009). Bicarbonate supplementation slows progression of
CKD and improves nutritional status.
 Mahajan A, et al, (2010). Daily oral sodium bicarbonate preserves glomerular
filtration rate by slowing its decline in early hypertensive nephropathy.
 DeFronzo RA, et al, (2022). Modifying chronic kidney disease progression with the
mineralocorticoid receptor antagonist finer none in patients with type II diabetes.
2/13/2024
Rebira W. (AHN student)
37
Stay Bless!

Más contenido relacionado

Similar a CGN Presentation by Rebira Workineh.pptx

uremia, treatment, symptoms , 12222.pptx
uremia, treatment, symptoms , 12222.pptxuremia, treatment, symptoms , 12222.pptx
uremia, treatment, symptoms , 12222.pptx
ddjumanalieva97
 
Complications of type 2 Diabetes mellitus
Complications of type 2 Diabetes mellitusComplications of type 2 Diabetes mellitus
Complications of type 2 Diabetes mellitus
Debajyoti Chakraborty
 

Similar a CGN Presentation by Rebira Workineh.pptx (20)

Chronic glomerulonephritis
Chronic glomerulonephritisChronic glomerulonephritis
Chronic glomerulonephritis
 
Chronic Glomerulonephritis.pptx
Chronic Glomerulonephritis.pptxChronic Glomerulonephritis.pptx
Chronic Glomerulonephritis.pptx
 
Chronic renal failure update on diagnostic tests
Chronic renal failure update on diagnostic testsChronic renal failure update on diagnostic tests
Chronic renal failure update on diagnostic tests
 
Chronic kidney disease(CKD) BY DR.MULLAPUDI RAMAKRISHNA
Chronic kidney disease(CKD) BY DR.MULLAPUDI RAMAKRISHNAChronic kidney disease(CKD) BY DR.MULLAPUDI RAMAKRISHNA
Chronic kidney disease(CKD) BY DR.MULLAPUDI RAMAKRISHNA
 
CKD PPT DOC.pptx
CKD PPT DOC.pptxCKD PPT DOC.pptx
CKD PPT DOC.pptx
 
uremia, treatment, symptoms , 12222.pptx
uremia, treatment, symptoms , 12222.pptxuremia, treatment, symptoms , 12222.pptx
uremia, treatment, symptoms , 12222.pptx
 
Kidney and scd
Kidney and scdKidney and scd
Kidney and scd
 
26 ckd by mersha
26 ckd by mersha26 ckd by mersha
26 ckd by mersha
 
Pharmacotherapy of Chronic Renal Failure Detailed.pptx
Pharmacotherapy of Chronic Renal Failure Detailed.pptxPharmacotherapy of Chronic Renal Failure Detailed.pptx
Pharmacotherapy of Chronic Renal Failure Detailed.pptx
 
kidney disease in HIV-positive patients, Moh'd sharshir
kidney disease in HIV-positive patients, Moh'd sharshirkidney disease in HIV-positive patients, Moh'd sharshir
kidney disease in HIV-positive patients, Moh'd sharshir
 
Acute kidney injury in children.pptx
Acute kidney injury in children.pptxAcute kidney injury in children.pptx
Acute kidney injury in children.pptx
 
Chronic kidney disease
Chronic kidney diseaseChronic kidney disease
Chronic kidney disease
 
Complications of type 2 Diabetes mellitus
Complications of type 2 Diabetes mellitusComplications of type 2 Diabetes mellitus
Complications of type 2 Diabetes mellitus
 
uproach to anemia in ICU
uproach to anemia in ICUuproach to anemia in ICU
uproach to anemia in ICU
 
CHRONIC KIDNEY DISEASE-1.pdf
CHRONIC KIDNEY DISEASE-1.pdfCHRONIC KIDNEY DISEASE-1.pdf
CHRONIC KIDNEY DISEASE-1.pdf
 
CHRONIC KIDNEY DISEASE-1.pdf
CHRONIC KIDNEY DISEASE-1.pdfCHRONIC KIDNEY DISEASE-1.pdf
CHRONIC KIDNEY DISEASE-1.pdf
 
Aki an overview
Aki an overviewAki an overview
Aki an overview
 
Journal club.......
Journal club.......Journal club.......
Journal club.......
 
Management of renal vein thrombosis by Sunil Kumar Daha
Management of renal vein thrombosis by Sunil Kumar DahaManagement of renal vein thrombosis by Sunil Kumar Daha
Management of renal vein thrombosis by Sunil Kumar Daha
 
Chronic Kidney Disease (CKD)
Chronic Kidney Disease (CKD)Chronic Kidney Disease (CKD)
Chronic Kidney Disease (CKD)
 

Más de RebiraWorkineh

INSTRUMENT PROCESSING PRESENTATION BY MASTER REBIRA.pptx
INSTRUMENT PROCESSING PRESENTATION BY MASTER REBIRA.pptxINSTRUMENT PROCESSING PRESENTATION BY MASTER REBIRA.pptx
INSTRUMENT PROCESSING PRESENTATION BY MASTER REBIRA.pptx
RebiraWorkineh
 
CNS Pharmacology PresentationBy Daniel-1.pptx
CNS Pharmacology PresentationBy Daniel-1.pptxCNS Pharmacology PresentationBy Daniel-1.pptx
CNS Pharmacology PresentationBy Daniel-1.pptx
RebiraWorkineh
 
Urinary Catheterization presentation by Rebira.pptx
Urinary Catheterization presentation by Rebira.pptxUrinary Catheterization presentation by Rebira.pptx
Urinary Catheterization presentation by Rebira.pptx
RebiraWorkineh
 
Rebira Workineh Article Critical Appraisal.pptx
Rebira Workineh Article Critical Appraisal.pptxRebira Workineh Article Critical Appraisal.pptx
Rebira Workineh Article Critical Appraisal.pptx
RebiraWorkineh
 
Hernia Presentation presentation by Rebira pptx
Hernia Presentation presentation by Rebira pptxHernia Presentation presentation by Rebira pptx
Hernia Presentation presentation by Rebira pptx
RebiraWorkineh
 
Wound Management Presentation by Rebira.pptx
Wound Management Presentation by Rebira.pptxWound Management Presentation by Rebira.pptx
Wound Management Presentation by Rebira.pptx
RebiraWorkineh
 
Hernia Presentation by Master Rebira W.pptx
Hernia Presentation by Master Rebira W.pptxHernia Presentation by Master Rebira W.pptx
Hernia Presentation by Master Rebira W.pptx
RebiraWorkineh
 
Fluid and electrolyte by Dr. Dereje.pptx
Fluid and electrolyte by Dr. Dereje.pptxFluid and electrolyte by Dr. Dereje.pptx
Fluid and electrolyte by Dr. Dereje.pptx
RebiraWorkineh
 
Rx of Thyrodism by Dr. Wako.2014.0028.pdf
Rx of Thyrodism by Dr. Wako.2014.0028.pdfRx of Thyrodism by Dr. Wako.2014.0028.pdf
Rx of Thyrodism by Dr. Wako.2014.0028.pdf
RebiraWorkineh
 
Capter-5 Medical surgical nursing II by Dr. Letapdf
Capter-5 Medical surgical nursing II by Dr. LetapdfCapter-5 Medical surgical nursing II by Dr. Letapdf
Capter-5 Medical surgical nursing II by Dr. Letapdf
RebiraWorkineh
 

Más de RebiraWorkineh (20)

Fundamenta N.Presentation By Mr. Rebira.pptx
Fundamenta N.Presentation By Mr. Rebira.pptxFundamenta N.Presentation By Mr. Rebira.pptx
Fundamenta N.Presentation By Mr. Rebira.pptx
 
INSTRUMENT PROCESSING PRESENTATION BY MASTER REBIRA.pptx
INSTRUMENT PROCESSING PRESENTATION BY MASTER REBIRA.pptxINSTRUMENT PROCESSING PRESENTATION BY MASTER REBIRA.pptx
INSTRUMENT PROCESSING PRESENTATION BY MASTER REBIRA.pptx
 
CNS Pharmacology PresentationBy Daniel-1.pptx
CNS Pharmacology PresentationBy Daniel-1.pptxCNS Pharmacology PresentationBy Daniel-1.pptx
CNS Pharmacology PresentationBy Daniel-1.pptx
 
Roper_logan_tierney presentation by Rebira.pptx
Roper_logan_tierney presentation by Rebira.pptxRoper_logan_tierney presentation by Rebira.pptx
Roper_logan_tierney presentation by Rebira.pptx
 
Nursing Theory Seminar presentation by Rebira
Nursing Theory Seminar presentation by RebiraNursing Theory Seminar presentation by Rebira
Nursing Theory Seminar presentation by Rebira
 
Drugs for Schiezophrenia by Rebira Workineh.pptx
Drugs for Schiezophrenia by Rebira Workineh.pptxDrugs for Schiezophrenia by Rebira Workineh.pptx
Drugs for Schiezophrenia by Rebira Workineh.pptx
 
Urinary Catheterization presentation by Rebira.pptx
Urinary Catheterization presentation by Rebira.pptxUrinary Catheterization presentation by Rebira.pptx
Urinary Catheterization presentation by Rebira.pptx
 
7. constipation seminar presentation by Master Diriba pptx
7. constipation seminar presentation by Master Diriba pptx7. constipation seminar presentation by Master Diriba pptx
7. constipation seminar presentation by Master Diriba pptx
 
Rebira Workineh Article Critical Appraisal.pptx
Rebira Workineh Article Critical Appraisal.pptxRebira Workineh Article Critical Appraisal.pptx
Rebira Workineh Article Critical Appraisal.pptx
 
Hypertensive heart disease presentation.pptx
Hypertensive heart disease presentation.pptxHypertensive heart disease presentation.pptx
Hypertensive heart disease presentation.pptx
 
Glaucoma Seminar Presentation by Rebira.pptx
Glaucoma  Seminar Presentation by Rebira.pptxGlaucoma  Seminar Presentation by Rebira.pptx
Glaucoma Seminar Presentation by Rebira.pptx
 
Hernia Presentation presentation by Rebira pptx
Hernia Presentation presentation by Rebira pptxHernia Presentation presentation by Rebira pptx
Hernia Presentation presentation by Rebira pptx
 
Wound Management Presentation by Rebira.pptx
Wound Management Presentation by Rebira.pptxWound Management Presentation by Rebira.pptx
Wound Management Presentation by Rebira.pptx
 
Hernia Presentation by Master Rebira W.pptx
Hernia Presentation by Master Rebira W.pptxHernia Presentation by Master Rebira W.pptx
Hernia Presentation by Master Rebira W.pptx
 
Fluid and electrolyte by Dr. Dereje.pptx
Fluid and electrolyte by Dr. Dereje.pptxFluid and electrolyte by Dr. Dereje.pptx
Fluid and electrolyte by Dr. Dereje.pptx
 
Rx of Thyrodism by Dr. Wako.2014.0028.pdf
Rx of Thyrodism by Dr. Wako.2014.0028.pdfRx of Thyrodism by Dr. Wako.2014.0028.pdf
Rx of Thyrodism by Dr. Wako.2014.0028.pdf
 
COPD, asthma presentation by Mr. Getupdf
COPD, asthma presentation by Mr. GetupdfCOPD, asthma presentation by Mr. Getupdf
COPD, asthma presentation by Mr. Getupdf
 
Capter-5 Medical surgical nursing II by Dr. Letapdf
Capter-5 Medical surgical nursing II by Dr. LetapdfCapter-5 Medical surgical nursing II by Dr. Letapdf
Capter-5 Medical surgical nursing II by Dr. Letapdf
 
Stroke presentation by Dr. Alemayew 4.ppt
Stroke presentation by Dr. Alemayew 4.pptStroke presentation by Dr. Alemayew 4.ppt
Stroke presentation by Dr. Alemayew 4.ppt
 
2. Congestive heart failure by Dawit.pptx
2. Congestive heart failure by Dawit.pptx2. Congestive heart failure by Dawit.pptx
2. Congestive heart failure by Dawit.pptx
 

Último

Último (20)

Telling Your Story_ Simple Steps to Build Your Nonprofit's Brand Webinar.pdf
Telling Your Story_ Simple Steps to Build Your Nonprofit's Brand Webinar.pdfTelling Your Story_ Simple Steps to Build Your Nonprofit's Brand Webinar.pdf
Telling Your Story_ Simple Steps to Build Your Nonprofit's Brand Webinar.pdf
 
The Benefits and Challenges of Open Educational Resources
The Benefits and Challenges of Open Educational ResourcesThe Benefits and Challenges of Open Educational Resources
The Benefits and Challenges of Open Educational Resources
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
 
Danh sách HSG Bộ môn cấp trường - Cấp THPT.pdf
Danh sách HSG Bộ môn cấp trường - Cấp THPT.pdfDanh sách HSG Bộ môn cấp trường - Cấp THPT.pdf
Danh sách HSG Bộ môn cấp trường - Cấp THPT.pdf
 
Pragya Champions Chalice 2024 Prelims & Finals Q/A set, General Quiz
Pragya Champions Chalice 2024 Prelims & Finals Q/A set, General QuizPragya Champions Chalice 2024 Prelims & Finals Q/A set, General Quiz
Pragya Champions Chalice 2024 Prelims & Finals Q/A set, General Quiz
 
The impact of social media on mental health and well-being has been a topic o...
The impact of social media on mental health and well-being has been a topic o...The impact of social media on mental health and well-being has been a topic o...
The impact of social media on mental health and well-being has been a topic o...
 
Sectors of the Indian Economy - Class 10 Study Notes pdf
Sectors of the Indian Economy - Class 10 Study Notes pdfSectors of the Indian Economy - Class 10 Study Notes pdf
Sectors of the Indian Economy - Class 10 Study Notes pdf
 
How to Create Map Views in the Odoo 17 ERP
How to Create Map Views in the Odoo 17 ERPHow to Create Map Views in the Odoo 17 ERP
How to Create Map Views in the Odoo 17 ERP
 
[GDSC YCCE] Build with AI Online Presentation
[GDSC YCCE] Build with AI Online Presentation[GDSC YCCE] Build with AI Online Presentation
[GDSC YCCE] Build with AI Online Presentation
 
An Overview of the Odoo 17 Discuss App.pptx
An Overview of the Odoo 17 Discuss App.pptxAn Overview of the Odoo 17 Discuss App.pptx
An Overview of the Odoo 17 Discuss App.pptx
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
 
The Last Leaf, a short story by O. Henry
The Last Leaf, a short story by O. HenryThe Last Leaf, a short story by O. Henry
The Last Leaf, a short story by O. Henry
 
MARUTI SUZUKI- A Successful Joint Venture in India.pptx
MARUTI SUZUKI- A Successful Joint Venture in India.pptxMARUTI SUZUKI- A Successful Joint Venture in India.pptx
MARUTI SUZUKI- A Successful Joint Venture in India.pptx
 
Morse OER Some Benefits and Challenges.pptx
Morse OER Some Benefits and Challenges.pptxMorse OER Some Benefits and Challenges.pptx
Morse OER Some Benefits and Challenges.pptx
 
Introduction to Quality Improvement Essentials
Introduction to Quality Improvement EssentialsIntroduction to Quality Improvement Essentials
Introduction to Quality Improvement Essentials
 
Basic phrases for greeting and assisting costumers
Basic phrases for greeting and assisting costumersBasic phrases for greeting and assisting costumers
Basic phrases for greeting and assisting costumers
 
Benefits and Challenges of Using Open Educational Resources
Benefits and Challenges of Using Open Educational ResourcesBenefits and Challenges of Using Open Educational Resources
Benefits and Challenges of Using Open Educational Resources
 
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
 
PART A. Introduction to Costumer Service
PART A. Introduction to Costumer ServicePART A. Introduction to Costumer Service
PART A. Introduction to Costumer Service
 
How to Break the cycle of negative Thoughts
How to Break the cycle of negative ThoughtsHow to Break the cycle of negative Thoughts
How to Break the cycle of negative Thoughts
 

CGN Presentation by Rebira Workineh.pptx

  • 1. Institute of Health Science Department of Nursing Postgraduate Program of Adult Health Nursing Chronic Glomerulonephritis Seminar Presentation Set By: Rebira Workineh (AHN Student) Rebira W. (AHN student) 2/13/2024 1
  • 2. Objectives Rebira W. (AHN student) At the end of this session, the participants will be able to:  Define chronic glomerulonephritis  Identify the development of chronic glomerulonephritis  Explain etiologies of chronic glomerulonephritis  Understand how to diagnose chronic glomerulonephritis  Describe the differential diagnosis of chronic glomerulonephritis  Identify possible management for patients with chronic glomerulonephritis 2/13/2024 2
  • 3. Outlines 2/13/2024 Rebira W. (AHN student) 3  Introduction to CGN  Epidemiology  Pathophysiology  Etiology  Clinical manifestations  Investigations  Differential diagnosis  Medical mgt.  Nursing mgt.  Prevention  Complications  References
  • 4. Introduction to CGN 2/13/2024 Rebira W. (AHN student) 4  Nearly all forms of AGN have a tendency to progress to chronic glomerulonephritis.  CGN is characterized by irreversible & progressive glomerular & tubulointerstitial fibrosis, leading to a reduction in the GFR & retention of uremic toxins.  If disease progression is not halted with therapy, it results in CKD, ESRD, & CVD.  CGN is the 3rd leading cause of CKD, & accounts for about 10% of all patients on dialysis. (Kawasaki Y et al, 2011)
  • 5. Introduction to CGN Cont’d… 2/13/2024 Rebira W. (AHN student) 5 Definition  CGN is a kidney disorder caused by slow, cumulative damage and scarring, usually by inflammation, of the tiny blood filters in the kidneys.  These filters, known as glomeruli, remove waste products from the blood.  Inflammation typically results in one or both of the nephrotic or nephritic syndromes.
  • 6. The National Kidney Foundation 2/13/2024 Rebira W. (AHN student) 6  NKF defines CKD on the basis of either of the following criteria o Evidence of kidney damage based on abnormal urinalysis results or structural abnormalities observed on ultrasound images o A GFR of < 60 mL/min for 3 months or longer According to this criteria, the NKF developed guidelines that classify the progression of renal disease into five stages  This classification includes treatment strategies for each progressive level as follow
  • 7. The NKF Cont’d… 2/13/2024 Rebira W. (AHN student) 7 Stage 1  This stage is characterized by kidney damage with a normal GFR - ≥ 90 mL/min  The action plan consists of diagnosis and treatment, treatment of comorbid conditions, slowing of the progressing of kidney disease, and reduction of CVD risks Stage 2  This stage is characterized by kidney damage with a mild decrease in the GFR- 60-90 mL/min  The action plan is estimation of the progression of kidney disease
  • 8. The NKF Cont’d… 2/13/2024 Rebira W. (AHN student) 8 Stage 3  This stage is characterized by a moderately decreased GFR- 30-59 mL/min  The action plan consists of evaluation and treatment of complications Stage 4  This stage is characterized by a severe decrease in the GFR - 15-29 mL/min  The action plan is preparation for renal replacement therapy Stage 5  This stage is characterized by kidney failure  The action plan is kidney replacement if the patient is uremic
  • 9. Epidemiology 2/13/2024 Rebira W. (AHN student) 9  In the United States, CGN is the 3rd leading cause of ESRD  It accounts for 10% of patients on dialysis  In Japan and some Asian countries, CGN has accounted for as many as 40% of patients on dialysis  However, subsequent data suggest that in Japan, the rate of CGN in patients on dialysis is 28%.  The cause of this decline rate is not known (Nakai S et al, 2004)
  • 11. Etiology 2/13/2024 Rebira W. (AHN student) 11  The progression from AGN to CGN is variable, based on the cause of the condition  Complete recovery of renal function occurs in patients with poststreptococcal glomerulonephritis  Other glomerulonephritis, such as IgA nephropathy, often has a relatively benign course  Many do not progress to ESRD  Progression patterns may be summarized as follows
  • 12. Etiology Cont’d… 2/13/2024 Rebira W. (AHN student) 12 Rapidly progressive glomerulonephritis or crescentic glomerulonephritis  About 90% of patients progress to ESRD within weeks or months Focal segmental glomerulosclerosis  About 80% of patients progress to ESRD in 10 years  This form may be related to HIV infection Membranous nephropathy  About 20-30% of patients with membranous nephropathy progress to CRF & ESRD in 10 years
  • 13. Etiology Cont’d… 2/13/2024 Rebira W. (AHN student) 13 Membranoproliferative glomerulonephritis  About 40% of patients with membranoproliferative glomerulonephritis progress to CRF & ESRD in 10 years IgA nephropathy  About 10% of patients with IgA nephropathy progress to CRF & ESRD in 10 years Poststreptococcal glomerulonephritis  About 1-2% of patients with poststreptococcal glomerulonephritis progress to CKD & ESRD
  • 14. Etiology Cont’d… 2/13/2024 Rebira W. (AHN student) 14 Lupus nephritis  About 20% of patients with lupus nephritis progress to CRF& ESRD in 10 years  The presence of antineutrophil cytoplasmic antibody is also an independent risk factor for poor renal outcome. (Wang Y et al, 2016)
  • 15. Pathophysiology 2/13/2024 Rebira W. (AHN student) Reduction in nephron mass from the initial injury reduces the GFR This reduction leads to hypertrophy and hyperfiltration of the remaining nephrons and to the initiation of intraglomerular hypertension These changes occur in order to increase the GFR of the remaining nephrons, thus minimizing the functional consequences of nephron loss 15 The changes, however, are ultimately detrimental because they lead to glomerulosclerosis & further nephron loss
  • 16. Pathophysiology Cont’d… 2/13/2024 Rebira W. (AHN student) 16  In early renal disease, decline in the GFR leads to slight increases in serum creatinine levels  Azotemia (i.e., a rise in blood urea nitrogen & serum creatinine levels) is apparent when the GFR decreases to < 60-70 mL/min  Reduction in the GFR also results in the following
  • 17. Pathophysiology Cont’d… 2/13/2024 Rebira W. (AHN student) 17  Decreased production of erythropoietin, thus resulting in anemia  Decreased production of vitamin D, resulting in hypocalcemia, secondary hyperparathyroidism, hyperphosphatemia, & renal osteodystrophy  Reduction in acid, potassium, salt, and water excretion, resulting in acidosis, hyperkalemia, hypertension, & edema  Platelet dysfunction, leading to increased bleeding tendencies
  • 18. Clinical Manifestations 2/13/2024 Rebira W. (AHN student) 18 Symptoms  Weakness and fatigue  Loss of energy, appetite, and weight  Pruritus  Early morning nausea and vomiting  Change in taste sensation  Reversal in sleep pattern  Peripheral neuropathy  Seizures  Tremors
  • 19. Clinical Cont’d… 2/13/2024 Rebira W. (AHN student) 19 Signs  Hypertension  Jugular venous distention  Pulmonary rales  Pericardial friction rubs in pericarditis  Tenderness in the epigastric region or blood in the stool  Decreased sensation and asterixis
  • 20. Investigations 2/13/2024 Rebira W. (AHN student) 20 Clinical findings  History collection  Physical examination Urinalysis  The presence of dysmorphic RBCs, albumin, or RBC casts suggest glomerulonephritis as the cause of kidney failure (Edgar V Lerma et al, 2022)
  • 21. Investigations Cont’d… 2/13/2024 Rebira W. (AHN student) 21 Urinary protein excretion  Estimated by calculating the protein to creatinine ratio on spot morning urine sample Complete blood count  Anemia is a significant finding in patients with some decline in the GFR  Is the result of marked impairment of erythropoietin production & alterations in iron absorption that accompany CKD from ferroprotein and FGF23
  • 22. Investigations Cont’d… 2/13/2024 Rebira W. (AHN student) 22 Serum chemistry  Serum creatinine & BUN levels are elevated  Impaired excretion of potassium, free water, & acid results in hyperkalemia, hyponatremia, and low serum bicarbonate levels, respectively  Impaired vitamin D-3 production results in hypocalcemia, hyperphosphatemia, and high levels of parathyroid hormone  Low serum albumin levels may be present if uremia interferes with nutrition or if the patient is nephrotic
  • 23. Investigations Cont’d… 2/13/2024 Rebira W. (AHN student) 23 Renal biopsy  Kidney biopsy is usually unnecessary Imaging Studies  Ultrasound: Presence of both kidneys, size & exclude structural lesions that may be responsible for azotemia
  • 24. Differential Diagnosis 2/13/2024 Rebira W. (AHN student) 24  Azotemia, uremia, chronic kidney disease  Crescentic glomerulonephritis  Diffuse proliferative glomerulonephritis  Glomerulonephritis associated with non-streptococcal infection  Membranoproliferative glomerulonephritis  Membranous glomerulonephritis  Poststreptococcal glomerulonephritis  Rapidly progressive glomerulonephritis
  • 25. Management- Diet & Activity 2/13/2024 Rebira W. (AHN student) 25 Diet  Protein restriction (0.4 to 0.6 mg/kg/day)  Slow the decline in GFR and reduce hyperphosphatemia (serum phosphate > 5.5 mg/dl) in patient with serum creatinine levels > 4 mg/dl  Should follow low potassium diets (2000-3000 mg/dl) Activity  Patient should increase their activity level as tolerated  This may aid in blood pressure control
  • 26. Pharmacologic Therapy 2/13/2024 Rebira W. (AHN student) 26 BP Management  Angiotensin converting enzyme inhibitors are the first treatment of choice  Angiotensin II receptor blockers are used to retard the progression of CKD in patient with diabetic and nondiabetic nephropathy  Combination of ACEIs and ARBs- to achieve better pressure control & preservation of kidney function
  • 27. Pharmacologic… 2/13/2024 Rebira W. (AHN student) 27 Diuretics  Are used to treat edema & hypertension  Increase urine excretion by inhibiting sodium and chloride transporters  Loop and thiazide are among classes of diuretics  Examples: Furosemide (Lasix), bumetanide, torsemide, ethacrynic acid & hydrochlorothiazide, metolazone  Others: Beta blockers, calcium channel blockers, alpha1 antagonists, direct vasodilators, etc.
  • 28. Pharmacologic… 2/13/2024 Rebira W. (AHN student) 28 Fibrosis inhibition  Progressive fibrosis is the hallmark of chronic glomerulonephritis  Inhibitors of fibrosis is intended to slow the progression  Pirfenidone is the best candidate, inhibits transforming growth factor & collagen synthesis  Others: Mineralocorticoid antagonists, nonsteroidal mineralocorticoid antagonists (better, b/c the former induce hyperkalemia) (DeFronzo RA et al ,2022)
  • 29. Pharmacologic… 2/13/2024 Rebira W. (AHN student) 29 Sodium bicarbonate  Reduce tubulointerstitial injury & endothelin production  Slow progressive kidney damage  In one study on patients with advanced kidney failure, the administration of sodium bicarbonate preserved GFR decline  Even in patients with relatively preserved GFR in stage 2 CKD, the administration of sodium bicarbonate was shown to preserve kidney function over 5 years (I de Brito-Ashurst et al, 2009 & Mahajan A et al, 2010)
  • 30. Renal Replacement Therapy 2/13/2024 Rebira W. (AHN student) 30  These options of renal replacement therapy are used when GFR falls below 20-25 ml/min  Renal transplantation must explored when GFR falls below 20 ml/min  Hemodialysis  Peritoneal dialysis  Renal transplantation
  • 31. Nursing Management 2/13/2024 Rebira W. (AHN student) 31 Nursing diagnosis Acute pain R/T inflammation of renal cortex AEB facial expressions & verbalization of patient Goals To reduce pain Intervention Assess pain characteristics Provide comfort devices, quite environment and calm activities Administer the analgesic according to physician order
  • 32. Nursing Management Cont’d… 2/13/2024 Rebira W. (AHN student) 32 Nursing diagnosis  Excess fluid volume R/T accumulation of fluid in the body AEB edema & weight gain. Goal  To maintain the fluid volume Intervention  To change the position frequently  To elevate the edematous extremities  To administer the diuretics to promote the diuresis  To administer the albumin helps in shifting the fluid from the ISC to IVC
  • 33. Nursing Management Cont’d… 2/13/2024 Rebira W. (AHN student) 33 Nursing diagnosis  Ineffective breathing pattern R/T accumulation of fluid in the peritoneal cavity AEB respiration rate, dyspnea. Goal  To improve the breathing pattern Intervention  Instruct the patient to perform the deep breathing exercise  To provide the semi-fowler position  Encourage the rest between the activities to avoid the overexertion
  • 34. Prevention 2/13/2024 Rebira W. (AHN student) 34  One should seek medical assistance as soon as possible if they have impetigo or a sore throat due to a strep infection.  Follow safe-sex guidelines and abstain from intravenous drug use to prevent infections like HIV & hepatitis, which can cause some types of glomerulonephritis.  Control high blood pressure to reduce the risk of kidney damage from hypertension.  In order to help avoid diabetic nephropathy, control blood sugar.
  • 35. Complication  Metabolic acidosis  Pericarditis, pulmonary edema  Uremic encephalopathy  Uremic gastrointestinal bleeding  Uremic neuropathy  Severe anemia & hypocalcaemia  Hyperkalemia 2/13/2024 Rebira W. (AHN student) 35
  • 36. References 2/13/2024 Rebira W. (AHN student) 36  Kawasaki Y, (2011). Mechanism of onset and exacerbation of chronic glomerulonephritis and its treatment.  Nakai S, et al, (2006). An overview of regular dialysis treatment in Japan (as of 31 December 2004).  de Brito-Ashurst I, et al, (2009). Bicarbonate supplementation slows progression of CKD and improves nutritional status.  Mahajan A, et al, (2010). Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy.  DeFronzo RA, et al, (2022). Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finer none in patients with type II diabetes.
  • 37. 2/13/2024 Rebira W. (AHN student) 37 Stay Bless!